EQUINOX NEPREMICNINE d.d Balance Sheet Health
Financial Health criteria checks 4/6
EQUINOX NEPREMICNINE d.d has a total shareholder equity of €39.8M and total debt of €8.9M, which brings its debt-to-equity ratio to 22.3%. Its total assets and total liabilities are €53.3M and €13.4M respectively. EQUINOX NEPREMICNINE d.d's EBIT is €367.3K making its interest coverage ratio -0.6. It has cash and short-term investments of €3.7M.
Key information
22.3%
Debt to equity ratio
€8.89m
Debt
Interest coverage ratio | -0.6x |
Cash | €3.65m |
Equity | €39.83m |
Total liabilities | €13.45m |
Total assets | €53.28m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EQNX's short term assets (€4.3M) exceed its short term liabilities (€1.4M).
Long Term Liabilities: EQNX's short term assets (€4.3M) do not cover its long term liabilities (€12.1M).
Debt to Equity History and Analysis
Debt Level: EQNX's net debt to equity ratio (13.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EQNX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: EQNX's debt is well covered by operating cash flow (64.2%).
Interest Coverage: EQNX earns more interest than it pays, so coverage of interest payments is not a concern.